|
Revision surgery performed on (b)(6) 2025, due to osteolysis.The patient underwent primary surgery in 2017 and received an anatomic shoulder replacement utilizing smr humeral components and std 3-pegged cemented glenoid.Due to glenoid implant loosening over time, osteolysis caused significant amount of glenoid bone loss.The following components were removed and dbm and cancellous bone chips were used to graft in the glenoid: - smr humeral head ø50 mm (part code 1322.09.500, lot number 1707513, sterilization 1700273).- smr ecc.Adaptor taper standard (part code 1330.15.274, lot number 1711206, sterilization 1700318).- smr trauma hum.Body # medium (part code 1350.15.010, lot number 1710020, sterilization 1700311).- cement.Glenoid 3 pegs standard (part code 1379.50.010, lot number 15at22u, sterilization 1600115).New humeral body, adapter, and humeral head were implanted on (b)(6) 2025, and the patient currently has a hemi arthroplasty until a second procedure can be undergone in the future to implant a baseplate.Previous surgery took place on (b)(6) 2017.The patient is a male, date of birth (b)(6) 1953.The event happened in the united states.
|
|
Investigation: checking the manufacturing charts of the glenoid component removed in this revision surgery, no pre-existing anomaly was discovered in the (b)(4) items belonging to the lot number 15at22u and sterilization number 1600115.This is the first and only complaint registered regarding this lot number.We did not receive any additional information on this event (i.E., x-rays), therefore we are not able to carry out any further investigation about the cause of the osteolysis reported.However, taking into account that: - no pre-existing anomalies were found by checking the manufacturing charts of the glenoid component removed in the revision surgery hereby reported we have no evidence to consider the event as product related.Pms data according to the available pms data, the revision rate of the cemented glenoids 3 pegs belonging to the family product code 1379.50.Xxx due to loosening is around 0.14%.Based on the root cause analysis performed and according to the relevant pms data, no corrective actions are required for this specific case.The manufacturer will continue monitoring the market to promptly detect any further similar issues.Note: this is a combined initial-final mdr.
|